153 related articles for article (PubMed ID: 15658857)
1. Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
Rahnasto M; Raunio H; Poso A; Wittekindt C; Juvonen RO
J Med Chem; 2005 Jan; 48(2):440-9. PubMed ID: 15658857
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes.
Asikainen A; Tarhanen J; Poso A; Pasanen M; Alhava E; Juvonen RO
Toxicol In Vitro; 2003 Aug; 17(4):449-55. PubMed ID: 12849728
[TBL] [Abstract][Full Text] [Related]
3. Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme--an in silico approach.
Rahnasto M; Wittekindt C; Juvonen RO; Turpeinen M; Petsalo A; Pelkonen O; Poso A; Stahl G; Höltje HD; Raunio H
Pharmacogenomics J; 2008 Oct; 8(5):328-38. PubMed ID: 17923852
[TBL] [Abstract][Full Text] [Related]
4. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice.
Siu EC; Tyndale RF
J Pharmacol Exp Ther; 2008 Mar; 324(3):992-9. PubMed ID: 18065502
[TBL] [Abstract][Full Text] [Related]
5. Conceptual DFT properties-based 3D QSAR: analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
Van Damme S; Bultinck P
J Comput Chem; 2009 Sep; 30(12):1749-57. PubMed ID: 19090569
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel CYP2A6 inhibitors by virtual screening.
Rahnasto MK; Raunio HA; Wittekindt C; Salminen KA; Leppänen J; Juvonen RO; Poso A; Lahtela-Kakkonen MK
Bioorg Med Chem; 2011 Dec; 19(23):7186-93. PubMed ID: 22019468
[TBL] [Abstract][Full Text] [Related]
7. Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization.
Yano JK; Denton TT; Cerny MA; Zhang X; Johnson EF; Cashman JR
J Med Chem; 2006 Nov; 49(24):6987-7001. PubMed ID: 17125252
[TBL] [Abstract][Full Text] [Related]
8. More potent inhibition of human CYP2A6 than mouse CYP2A5 enzyme activities by derivatives of phenylethylamine and benzaldehyde.
Rahnasto M; Raunio H; Poso A; Juvonen RO
Xenobiotica; 2003 May; 33(5):529-39. PubMed ID: 12746108
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of neurotransmitters and steroids on human CYP2A6.
Higashi E; Nakajima M; Katoh M; Tokudome S; Yokoi T
Drug Metab Dispos; 2007 Apr; 35(4):508-14. PubMed ID: 17237153
[TBL] [Abstract][Full Text] [Related]
10. Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6.
Denton TT; Zhang X; Cashman JR
Biochem Pharmacol; 2004 Feb; 67(4):751-6. PubMed ID: 14757175
[TBL] [Abstract][Full Text] [Related]
11. 5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.
Denton TT; Zhang X; Cashman JR
J Med Chem; 2005 Jan; 48(1):224-39. PubMed ID: 15634016
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.
Draper AJ; Madan A; Parkinson A
Arch Biochem Biophys; 1997 May; 341(1):47-61. PubMed ID: 9143352
[TBL] [Abstract][Full Text] [Related]
13. Pronounced differences in inhibition potency of lactone and non-lactone compounds for mouse and human coumarin 7-hydroxylases (CYP2A5 and CYP2A6).
Juvonen RO; Gynther J; Pasanen M; Alhava E; Poso A
Xenobiotica; 2000 Jan; 30(1):81-92. PubMed ID: 10659953
[TBL] [Abstract][Full Text] [Related]
14. Nicotine metabolism and urinary elimination in mouse: in vitro and in vivo.
Raunio H; Pokela N; Puhakainen K; Rahnasto M; Mauriala T; Auriola S; Juvonen RO
Xenobiotica; 2008 Jan; 38(1):34-47. PubMed ID: 18098062
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.
Zhang W; Kilicarslan T; Tyndale RF; Sellers EM
Drug Metab Dispos; 2001 Jun; 29(6):897-902. PubMed ID: 11353760
[TBL] [Abstract][Full Text] [Related]
16. Role of human cytochrome P4502A6 in C-oxidation of nicotine.
Nakajima M; Yamamoto T; Nunoya K; Yokoi T; Nagashima K; Inoue K; Funae Y; Shimada N; Kamataki T; Kuroiwa Y
Drug Metab Dispos; 1996 Nov; 24(11):1212-7. PubMed ID: 8937855
[TBL] [Abstract][Full Text] [Related]
17. Different modes of inhibition of mouse Cyp2a5 and rat CYP2A3 by the food-derived 8-methoxypsoralen.
Visoni S; Meireles N; Monteiro L; Rossini A; Pinto LF
Food Chem Toxicol; 2008 Mar; 46(3):1190-5. PubMed ID: 18215451
[TBL] [Abstract][Full Text] [Related]
18. Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5.
Siu EC; Wildenauer DB; Tyndale RF
Psychopharmacology (Berl); 2006 Mar; 184(3-4):401-8. PubMed ID: 16485141
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice.
Damaj MI; Siu EC; Sellers EM; Tyndale RF; Martin BR
J Pharmacol Exp Ther; 2007 Jan; 320(1):250-7. PubMed ID: 17021260
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism.
von Weymarn LB; Brown KM; Murphy SE
J Pharmacol Exp Ther; 2006 Jan; 316(1):295-303. PubMed ID: 16188955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
